TORONTO, ON / ACCESSWIRE / January 13, 2016 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSX-V: TLT) (OTC: TLTFF), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that Michael Borovec, Director of Investor Relations will present at the NobleCon12 - Noble Financial Capital Markets' Twelfth Annual Investor Conference at Club Med in Florida, on Tuesday, January 19th at 3:00 pm EST in Room 3.
Following the Conference on January 22, 2016, a high-definition video webcast of Theralase's presentation and a copy of the presentation materials will be available on the Company's web site www.theralase.com or as part of a complete catalog of presentations available at Noble Financial websites: www.noblefcm.com, or nobleconference.com. You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will be archived on the company's website and on the Noble websites for 90 days following the event.
About Noble Financial Capital Markets
Noble Financial Capital Markets established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton, New York, Boston and Los Angeles. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous "non-deal" corporate road shows and sector-specific conferences.
About Theralase Technologies Inc.
Theralase Technologies Inc. ("Theralase(R)") (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase's Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.
Theralase Technologies Inc. was recognized as a TSX Venture 50(R) company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
SOURCE: Theralase Technologies Inc.